**Review Article**
Volume 7:5, 2023

Journal of Interventional and General Cardiology

ISSN: 2684-4591 Open Access

# Rheumatoid Arthritis is an Autoimmune Disease Including the Cardiovascular System

**Kathryn Berlacher***

*Department of Cardiology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA*

## Abstract

Rheumatoid arthritis is an autoimmune disease that primarily affects the joints. It is characterized by chronic inflammation, pain, stiffness, and joint deformity. RA is not limited to the joints, as it can also affect other organs and systems in the body, including the cardiovascular system. Over the years, extensive research has revealed a significant association between RA and an increased risk of cardiovascular disease. Individuals with RA have a higher likelihood of experiencing heart attacks, strokes, and other cardiovascular events compared to the general population. Inflammation plays a central role in the pathophysiology of RA, contributing to joint damage and systemic complications. The chronic inflammation observed in RA can lead to endothelial dysfunction, atherosclerosis and increased cardiovascular risk.

**Keywords:** Rheumatoid arthritis • Pathophysiology • Atherosclerosis • Hypertension

## Introduction

Several inflammatory markers have been studied in the context of RA and CVD, with one of the most widely investigated being C-reactive protein. CRP is an acute-phase protein produced by the liver in response to inflammation. Its levels rise quickly in response to infections, tissue damage and various inflammatory conditions. CRP is often used as a marker of systemic inflammation and has been studied extensively in the context of cardiovascular risk assessment, both in the general population and among individuals with inflammatory conditions such as RA. In individuals with RA, CRP levels are often elevated due to the ongoing systemic inflammation. These elevated CRP levels can persist even when joint symptoms are well-controlled or in remission, reflecting the chronic nature of the disease. Given that RA itself is associated with an increased cardiovascular risk, researchers have sought to understand how CRP levels in RA patients may relate to their cardiovascular risk. Numerous studies have explored the association between CRP levels and cardiovascular risk in RA patients. Elevated CRP levels in RA have been found to predict future cardiovascular events, including heart attacks and strokes. Individuals with higher CRP levels tend to have a higher risk of developing CVD. CRP levels have prognostic value in RA patients who already have established cardiovascular disease. Higher CRP levels in these individuals are associated with worse cardiovascular outcomes. There appears to be a dose-response relationship between CRP levels and cardiovascular risk in RA. In other words, as CRP levels increase, the cardiovascular risk also rises. If CRP is elevated, healthcare providers may prioritize more aggressive anti-inflammatory treatment strategies to not only control joint inflammation but also reduce cardiovascular risk. Serial measurements of CRP can be used to monitor a patient's response to anti-inflammatory treatments [1].

## Literature Review

CRP is considered an independent risk factor for CVD in RA, meaning it contributes to cardiovascular risk beyond traditional risk factors such as hypertension, smoking, and dyslipidemia. Lowering CRP levels through anti-inflammatory treatment strategies has been associated with improved cardiovascular outcomes in RA patients. This suggests that reducing inflammation may mitigate cardiovascular risk. One way to assess cardiovascular risk is by estimating the likelihood of experiencing a cardiovascular event, such as a heart attack or stroke, within a specific timeframe, typically 10 years. Various risk assessment tools and scoring systems are available to calculate an individual's 10-year cardiovascular risk based on factors such as age, gender, blood pressure, cholesterol levels, smoking status, and diabetes. These tools help healthcare providers identify patients who may benefit from preventive measures such as lifestyle modifications or pharmacological interventions. In recent years, researchers and clinicians have explored the potential role of CRP in improving cardiovascular risk assessment in RA patients. CRP can be considered as an additional biomarker when assessing cardiovascular risk in RA patients. It provides valuable information about the level of underlying inflammation, which is a key driver of cardiovascular risk in this population. Incorporating CRP levels into cardiovascular risk assessment allows for a more personalized approach to risk stratification. RA patients with elevated CRP levels may be classified as higher-risk individuals who require more aggressive risk reduction strategies. The knowledge of CRP levels can influence treatment decisions in RA. A decrease in CRP levels may indicate improved control of inflammation and potentially reduced cardiovascular risk [2].

## Discussion

While elevated CRP is associated with increased risk, it is not necessarily the direct cause of cardiovascular events. RA is a heterogeneous disease, and not all patients with RA have elevated CRP levels. Other factors, such as genetic predisposition, may also play a role in cardiovascular risk. The effects of anti-inflammatory treatments on CRP levels can vary among individuals. Some patients may achieve significant reductions in CRP with treatment, while others may not respond as well. Incorporating CRP testing into routine care may have cost and accessibility implications. Not all healthcare settings may have easy access to CRP testing, especially in resource-limited areas. Further refinement of cardiovascular risk assessment models that incorporate CRP levels, potentially considering other inflammatory markers as well. Conducting clinical trials to evaluate the impact of anti-inflammatory therapies on cardiovascular outcomes in RA patients with elevated CRP. Advancing the development of personalized cardiovascular risk assessment and management strategies for individuals with RA based on their specific clinical and inflammatory profiles. Promoting awareness among both healthcare providers and patients about the importance of inflammation control in reducing cardiovascular risk in RA.

***Address for Correspondence:** Kathryn Berlacher, Department of Cardiology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA, E-mail: Kathrynberlacher4@gmail.com*



**Received:** 01 September, 2023, Manuscript No. jigc-23-116517; **Editor assigned:** 04 September, 2023, PreQC No. P-116517; **Reviewed:** 14 September, 2023, QC No. Q-116517; **Revised:** 19 September, 2023, Manuscript No. R-116517; **Published:** 26 September, 2023, DOI: 10.37421/2684-4591.2023.7.211

C-reactive protein has emerged as a valuable biomarker in the assessment of cardiovascular risk in individuals with rheumatoid arthritis. Elevated CRP levels are associated with an increased risk of cardiovascular events, and incorporating CRP into cardiovascular risk assessment may help identify RA patients at higher risk who could benefit from more aggressive risk reduction strategies. However, the integration of CRP into clinical practice requires careful consideration of its limitations and the need for further research to establish causality and refine risk assessment models [3].

Ultimately, a comprehensive approach that combines traditional cardiovascular risk factors, inflammatory markers like CRP, and personalized treatment strategies holds promise in reducing the burden of cardiovascular disease in RA patients. Cardiovascular disease is a leading cause of morbidity and mortality worldwide. Rheumatoid arthritis a chronic autoimmune inflammatory disorder is associated with an increased risk of CVD. While traditional risk factors such as hypertension and hypercholesterolemia play a role in CVD development, inflammation is emerging as a crucial contributor in patients with RA. C-reactive protein is a sensitive marker of systemic inflammation and has been studied extensively in the context of CVD risk in RA. This article explores the relationship between CRP levels and the 10-year cardiovascular risk in patients with rheumatoid arthritis, examining the underlying mechanisms, clinical implications, and potential interventions. Rheumatoid arthritis is characterized by chronic inflammation that primarily affects the joints but can also involve other organs, including the heart and blood vessels. The chronic inflammatory state in RA contributes to endothelial dysfunction, atherosclerosis, and an increased risk of cardiovascular events, such as heart attacks and strokes. Persistent inflammation in RA leads to the release of proinflammatory cytokines, which promote endothelial dysfunction and plaque formation in blood vessels. Autoimmune processes can target the blood vessel walls, contributing to inflammation and atherosclerosis. Patients with RA often have an increased prevalence of traditional cardiovascular risk factors, such as hypertension, hyperlipidemia, and obesity, which further elevate their CVD risk [4].

Some medications used to manage RA, such as corticosteroids, can have adverse effects on cardiovascular health. C-reactive protein is an acute-phase reactant produced by the liver in response to inflammation, infection, or tissue injury. It is one of the most widely studied inflammatory markers in the context of CVD. CRP levels can be measured through a simple blood test, and elevated CRP is indicative of systemic inflammation. High-sensitivity CRP assays have enhanced sensitivity and are particularly useful in evaluating low-grade chronic inflammation, such as that seen in RA. The role of CRP in cardiovascular risk assessment is well-established in the general population. Elevated CRP levels have been shown to predict future cardiovascular events independently of traditional risk factors. In patients with RA, CRP takes on added significance due to the inflammatory nature of the disease. Several studies have investigated the association between CRP levels and cardiovascular risk in patients with RA. Elevated CRP levels are an independent predictor of CVD risk in RA, meaning that even after adjusting for traditional risk factors, CRP remains a significant contributor to cardiovascular risk. There appears to be a dose-response relationship between CRP levels and CVD risk, with higher CRP levels associated with a greater risk of cardiovascular events. Longitudinal studies have demonstrated that persistent elevation of CRP over time is associated with a higher risk of future cardiovascular events in RA patients. Effective treatment of RA with disease-modifying antirheumatic drugs and biologics is associated with a reduction in CRP levels and, subsequently, a decrease in cardiovascular risk. While the integration of CRP into cardiovascular risk assessment in RA is promising, there are challenges. Establishing a causal relationship between CRP levels and cardiovascular risk in RA is complex [5].

CRP can impair endothelial function, which is a crucial early step in atherosclerosis development. CRP is involved in the formation of atherosclerotic plaques by promoting inflammation within the vessel walls. Elevated CRP levels may increase the risk of thrombosis by altering blood clotting factors. CRP has been associated with insulin resistance, which is a risk factor for CVD. CRP may influence vascular remodeling, promoting the development of pathological changes in blood vessel structure. CRP levels can help stratify RA patients into different cardiovascular risk categories. Those with persistently elevated CRP levels may be considered at higher risk and may benefit from more aggressive cardiovascular risk reduction strategies. CRP can serve as a useful marker for monitoring disease activity and treatment response in RA. Effective RA management often leads to reductions in CRP levels, which can be associated with reduced cardiovascular risk. Therapies that specifically target inflammation in RA, such as biologics, have been shown to lower CRP levels and, by extension, may reduce cardiovascular risk. Patients with RA and elevated CRP levels may benefit from lifestyle interventions such as smoking cessation, weight management, and exercise, which can help reduce cardiovascular risk. Some experts suggest that CRP levels should be considered a therapeutic target in RA management. Lowering CRP through treatment may have a positive impact on cardiovascular risk reduction [6].

## Conclusion

In some cases, pharmacological interventions, such as statins or anti-inflammatory medications, may be considered to mitigate cardiovascular risk in RA patients with elevated CRP. Despite significant progress in understanding the role of CRP in cardiovascular risk assessment in RA, several areas warrant further investigation. While CRP is a valuable marker, exploring additional biomarkers of inflammation and endothelial dysfunction in RA may provide a more comprehensive assessment of cardiovascular risk. Research should continue to elucidate the most effective treatment strategies for reducing CRP levels and cardiovascular risk in RA patients. The timing of intervention to reduce cardiovascular risk in RA is an important research area. Determining when and how aggressively to intervene is crucial. Educating RA patients about the implications of elevated CRP levels on their cardiovascular risk can empower them to actively participate in their healthcare and risk reduction. This relationship underscores the importance of inflammation in the pathogenesis of cardiovascular disease in RA patients. CRP serves as a valuable marker for risk assessment and treatment response monitoring. Clinicians should consider incorporating CRP measurements into their cardiovascular risk assessments for RA patients, with the goal of reducing CVD morbidity and mortality in this high-risk population. Further research is needed to refine risk assessment strategies and optimize interventions for RA patients with elevated CRP levels.

## Acknowledgement

None.

## Conflict of Interest

None.

## References

1. Campbell, Norm RC, Pedro Ordunez, Gloria Giraldo and Yenny A. Rodriguez Morales, et al. "WHO HEARTS: A global program to reduce cardiovascular disease burden: Experience implementing in the Americas and opportunities in Canada." *Can J Cardiol* 37 (2021): 744-755.

2. Mineo, Chieko and Philip W. Shaul. "PON-dering differences in HDL function in coronary artery disease." *J Clin Investig* 121 (2011): 2545-2548.

3. Mackness, Michael I., Sharon Arrol and Paul N. Durrington. "Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein." *FEBS Letters* 286 (1991): 152-154.

4. Aviram, Michael and Jacob Vaya. "Paraoxonase 1 activities, regulation and interactions with atherosclerotic lesion." *Curr Opin Lipidol* 24 (2013): 339-344.

5. Pavanello, Chiara and Alice Ossoli. "HDL and chronic kidney disease." *Atheroscler Plus* 52 (2023): 9-17.

6. Holzer, Michael, Gernot Schilcher, Sanja Curcic and Markus Trieb, et al. "Dialysis modalities and HDL composition and function." *J Am Soc Nephrol* 26 (2015): 2267.

**How to cite this article:** Berlacher, Kathryn. "Rheumatoid Arthritis is an Autoimmune Disease Including the Cardiovascular System." *J Interv Gen Cardiol* 7 (2023): 211.